Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors

Documenti analoghi

• Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
  di: Jabbour, Elias, et al.
  Pubblicazione: (2009)
• Mutant BCR-ABL clones in chronic myeloid leukemia
  di: Mathisen, Michael S., et al.
  Pubblicazione: (2011)
• Practical Advice for Determining the Role of BCR-ABL Mutations in Guiding Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
  di: Jabbour, Elias, et al.
  Pubblicazione: (2010)
• Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
  di: Jain, Preetesh, et al.
  Pubblicazione: (2016)
• EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
  di: Jabbour, Elias, et al.
  Pubblicazione: (2012)